RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California and currently employs 0 full-time employees. The company went IPO on 2022-01-07. The firm is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The firm is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The firm is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.
Follow-Up Questions
Who is the CEO of RetinalGenix Technologies Inc?
Dr. Jerry Katzman is the President of RetinalGenix Technologies Inc, joining the firm since 2018.
What is the price performance of RTGN stock?
The current price of RTGN is $3.55, it has decreased 0% in the last trading day.
What are the primary business themes or industries for RetinalGenix Technologies Inc?
RetinalGenix Technologies Inc belongs to Health Care industry and the sector is Health Care
What is RetinalGenix Technologies Inc market cap?
RetinalGenix Technologies Inc's current market cap is $66.0M
